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a  b  s  t  r  a  c  t
Brentuximab  vedotin  was  available  via  named  patient  program  (NPP)  to patients  with relapsed/refractory
(R/R)  Hodgkin  lymphoma  (HL) or systemic  anaplastic  large-cell  lymphoma  in  ∼60 non-US/Canadian
countries,  before  local  approval.  Published  results  were  examined  recently;  through  systematic  literature
review,  we identiﬁed  12  new  NPP  publications.  Most  (10/12)  publications  included  new  NPP  data  describ-
ing  8  unique  cohorts  (N = 480;  all R/R HL) and new  participating  countries.  Overall  response  rates  were
58–80%,  and  complete  remission  rates  were  10–40%.  With  median  follow-up  of  9.5–26 months,  medianrentuximab vedotin
D30
odgkin lymphoma
amed patient program
progression-free  survival  was  5–10.5  months  and  median  overall  survival  (OS)  had not been  reached  in
most  cohorts;  1-  and 2-year  OS  was  67–76%  and 58–67%,  respectively.  Tolerability  was  as  expected  from
previous  reports.  Despite  intrinsic  bias  and  heterogeneous  cohorts,  this  update  supports  previous  ﬁnd-
ings  showing  comparable  efﬁcacy  and  tolerability  of brentuximab  vedotin  between  real-world  practice
and  phase  2 trial results  in  R/R  HL.
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1. Introduction
Prior to local regulatory approval, the CD30-targeted antibody-
drug conjugate, brentuximab vedotin, was  made available
for compassionate use in approximately 60 non-US/Canadian
countries via a Named Patient Program (NPP; Takeda Pharma-
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Table  1
Key characteristics of patients treated under the NPP.
Publication N (n in NPP) Country Treatment
dates
R/R HL, n Median age,
years (range)
Male, % Median
number of
prior therapies,
n (range)
Primary
refractory/no
response to last
prior therapy, %
Prior ASCT/
prior alloSCT, %
Update (including new patients) to cohort included in original review of NPP data
Erdem et al.
(2014)
10
(NR)
Turkey NR 10 26 (22–30) 80 4 (3–5)a 50/80 100/NR
Reports including new NPP patients with potential overlapb with cohorts included in original review of NPP data
Perrot et al.
(2014)
241
(241)
France Jan 2011–Jan
2014
241 34 (17–79) NR 3 (1–13)c 74/47d 61e/16
Viviani et al.
(2015)f
45
(NR)
Italy Jan 2011–Apr
2014
45 A: 38 (20–76)
B: 39 (18–64)
40 A: 4 (2–12)
B: 4 (2–9)
A: 75/NR
B: 68/NR
A: 0/NR
B: 100/NR
Salihoglu et al.
(2015)
(update of
congress
abstract,
Ferhanoglu
et al., 2014)
58
(58)
Turkey Mar 2011–Jul
2013
58 26 (13–62) 64 4 (2–7)c 49/72 83/17g
Reports of new NPP cohorts not included in original review of NPP data
Tsirigotis et al.
(2015)
80
(NR)
Greece Jun 2011–Aug
2014
80 32 (18–77) 54 4 (1–7) 67/65 79/3h
Carlo-Stella
et al. (2015)i
(update of
congress
abstract,
Ricci et al.,
2014i)
16
(16)
Italy Jun 2011–Jan
2014
16 29 (22–43) 81 8 (4–15) 31/88 100/100
Yang et al.
(2014)
22
(22)
Asia Oct 2011–Jun
2013
22 30 (16–57) 68 NR
(91% had
received ≥3
lines)
55/NR 77j
Zallio et al.
(2014)g
8
(NR)
Italy Aug 2011–Sep
2013
8 32 (21–61) NR 5 (NR) NR/NR 100/NR
AlloSCT, allogeneic stem cell transplant; ASCT, autologous stem cell transplant; HL, Hodgkin lymphoma; NPP, named patient program; NR, not reported; R/R,
relapsed/refractory.
a Excluding ASCT.
b Determined based on review of treatment dates for each report versus other reports from the same country included in the original review.
c Chemotherapy only.
d Patients progressive to last chemotherapy.
e Patients who  received ≥1 transplant (type not speciﬁed).
f Data for some parameters only available by group (A, patients ineligible for ASCT [n = 20]; B, patients who had failed prior ASCT [n = 25]).
g 49 patients in total (85%) had prior transplantation, 9 of whom had both prior ASCT and alloSCT.
h 76% of patients had relapsed/progressed after ASCT and 3% had failed both ASCT and alloSCT.
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riginal  literature review.
j ASCT and/or alloSCT (no breakdown by transplant type).
euticals International Co., Cambridge, MA,  USA). Patients with
elapsed/refractory (R/R), CD30-positive Hodgkin lymphoma (HL)
r systemic anaplastic large cell lymphoma (sALCL) who  met  the
S label criteria were eligible to participate. Clinical NPP data from
1 publications (identiﬁed by systematic literature review) have
ince been evaluated (Zinzani et al., 2015); efﬁcacy and tolerabil-
ty of brentuximab vedotin in real-world practice were similar to
hose reported in the registrational phase 2 trials in R/R HL and
ALCL (Pro et al., 2012; Younes et al., 2012). As additional data are
ow available, we have evaluated new reports of NPP outcomes
ith brentuximab vedotin to assess how they compare with the
revious NPP ﬁndings and pivotal phase 2 data.
. Methodology
Details of the systematic literature review used to identify NPP
ublications have been published previously (Zinzani et al., 2015).
mploying this methodology, search results (PubMed and pre-
peciﬁed congress abstract books) were updated for the period,
ecember 13, 2013 (data cut-off in the original review) to June 11,
015 (to include abstracts presented at the International Congress
n Malignant Lymphoma 2015). Search results were reviewedse reports describe unique NPP patient series versus Italian reports included in the
manually to identify original references reporting NPP data. Base-
line data, together with efﬁcacy and safety outcomes are reported.
3. Update of NPP efﬁcacy and safety data
3.1. Studies identiﬁed
Since December 13, 2013 (Zinzani et al., 2015), an additional
12 publications reporting NPP data were identiﬁed (Carlo-Stella
et al., 2015; Erdem et al., 2014; Ferhanoglu et al., 2014; Kahraman
et al., 2014; Monjanel et al., 2014; Perrot et al., 2014; Ricci
et al., 2014; Salihoglu et al., 2015; Tsirigotis et al., 2015; Viviani
et al., 2015; Yang et al., 2014; Zallio et al., 2014). Two publica-
tions (Erdem et al., 2014; Monjanel et al., 2014) were updates
to studies described in our previous review (Zinzani et al., 2015;
Erdem et al., 2012; Monjanel et al., 2013); as one of these studies
(describing a Turkish cohort of 10 patients) included ﬁve additional
patients, it has been included in this analysis (Erdem et al., 2014).
Another publication (Kahraman et al., 2014) evaluated the role of
18-ﬂuorodeoxyglucose positron emission tomography/computed
tomography for monitoring response to brentuximab vedotin; this
paper was excluded as the clinical data for this cohort had been
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Table  2
Brentuximab vedotin treatment and subsequent transplantation in patients with R/R HL treated under the NPP.
NPP cohort Brentuximab vedotin Transplantation
post-brentuximab
vedotin, n (%)
Dose (mg/kg), frequency Median number of cycles (range)
Erdem et al. (2014) 1.8, Q3wk NR (up to 16 cycles) ASCT: NR alloSCT: 6 (60)
Perrot  et al. (2014) 1.8, Q3wk 6 (1–16) ASCT: 29 (12)alloSCT: 27 (11)
Viviani et al. (2015) 1.8, Q3wk 6 (3–19) A: 7 (35)a,b B: 15 (60)a,b
Salihoglu et al. (2015)Ferhanoglu et al. (2014) 1.8, Q3wk 7 (2–18) ASCT: 2 (3.5) alloSCT: 12 (21)
Tsirigotis et al. (2015) 1.8, Q3wk 6 (1–6) NR
Carlo-Stella et al. (2015) Ricci et al. (2014) 1.8, Q3wk 8 (1–17) ASCT: NR alloSCT: 1 (6)c
Yang et al. (2014) 1.8, Q3wk 5 (1–18) NR
Zallio et al. (2014) NR, Q3wk 6 (4–7) ASCT: NRRIC alloSCT: 8 (100)
AlloSCT, allogeneic stem cell transplant; ASCT, autologous stem cell transplant; HL, Hodgkin lymphoma; NPP, named patient program; NR, not reported; Q3wk, every 3
weeks;  RIC, reduced-intensity conditioning; R/R, relapsed/refractory.
aData for some parameters only available by group (A, patients ineligible for ASCT [n = 20]; B, patients who  had failed prior ASCT [n = 25]).
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c One patient discontinued treatment with brentuximab vedotin due to availabili
his  transplant went ahead).
eported previously in two publications captured in the original
eview (Rothe et al., 2012; Theurich et al., 2013). Four further publi-
ations described 344 patients in French (Perrot et al., 2014), Italian
Viviani et al., 2015), and Turkish (Ferhanoglu et al., 2014; Salihoglu
t al., 2015) cohorts. These four publications were included in
he present analysis as they reported additional patients to those
dentiﬁed in our original searches. However, based on review of
reatment dates compared with other reports from the same coun-
ries, we could not discount that they also included patients who
ad been described previously. Lastly, ﬁve publications described
26 patients in four new cohorts not described in the original
eview. These patients cohorts were from Italy (two cohorts of 16
Carlo-Stella et al., 2015; Ricci et al., 2014) and 8 patients, respec-
ively (Zallio et al., 2014)), Greece (a single cohort of 80 patients
Tsirigotis et al., 2015)), and Asia (a single cohort of 22 patients
Yang et al., 2014)); one of the Asian patients may  have been
escribed previously in a case report (Cao et al., 2013)).
In total, 10 publications (Carlo-Stella et al., 2015; Erdem et al.,
014; Ferhanoglu et al., 2014; Perrot et al., 2014; Ricci et al., 2014;
alihoglu et al., 2015; Tsirigotis et al., 2015; Viviani et al., 2015;
ang et al., 2014; Zallio et al., 2014) included NPP data for eight
nique cohorts and 480 patients (Table 1). As stated above, for sev-
ral publications it has not been possible to determine the extent of
verlap with previous reports of NPP data. Additionally, some pub-
ications included non-NPP data, but did not provide a breakdown
f outcomes for the NPP and non-NPP cohorts.
.2. Patient characteristics
All 480 patients had R/R HL (Table 1). The most common median
umber of prior therapies was 4. Overall, 31–75% of patients had
rimary refractory HL, and 47–88% had no response to their last
rior therapy. Most patients (61–100%) had undergone prior ASCT,
nd (excluding one analysis looking speciﬁcally at patients who  had
ailed allogeneic SCT [alloSCT] (Carlo-Stella et al., 2015; Ricci et al.,
014)), up to 17% of patients had received prior alloSCT.
.3. Treatment exposure
Exposure to brentuximab vedotin and information regarding
ubsequent transplantation are presented in Table 2. In all cohorts
here the dosing schedule was fully reported, brentuximab vedotin
as administered intravenously at a dose of 1.8 mg/kg every 3
eeks. The median number of cycles of brentuximab vedotin
eceived ranged from 5 to 8 (Table 2). donor for a second alloSCT (no further information is provided regarding whether
3.4. Response and survival outcomes
Where detailed methods were reported, response to bren-
tuximab vedotin was  assessed by computed tomography
and/or positron-emission tomography (Carlo-Stella et al., 2015;
Ferhanoglu et al., 2014; Ricci et al., 2014; Salihoglu et al., 2015;
Yang et al., 2014). Best response data are shown in Table 3.
Responses were seen within a median of 3–4 treatment cycles, and
lasted for a median of 4–9 months. Overall response rates (ORR;
complete remission [CR] + partial remission [PR]) were typically
58–80%, although lower ORRs were reported in two studies where
response was  assessed later in therapy (Ferhanoglu et al., 2014;
Perrot et al., 2014; Salihoglu et al., 2015). CR rates were 10–40%.
Five publications describing four cohorts reported ORRs and CR
rates in the subset of patients with prior SCT (Carlo-Stella et al.,
2015; Erdem et al., 2014; Ricci et al., 2014; Viviani et al., 2015; Zallio
et al., 2014): 32/43 patients (74%) with prior ASCT (Erdem et al.,
2014; Viviani et al., 2015; Zallio et al., 2014), and 11/16 patients
(69%) with prior ASCT and alloSCT (Carlo-Stella et al., 2015; Ricci
et al., 2014) achieved an objective response. CRs were seen in 8/43
(19%) and 5/16 (31%) patients, respectively.
Most studies reported survival data; after a median follow-up of
9.5–26 months, median overall survival (OS) had not been reached
in most cohorts, although values of 25 months and 31 months were
reported in two studies (Carlo-Stella et al., 2015; Ricci et al., 2014;
Tsirigotis et al., 2015). One- and 2-year OS was 67–76% and 58–67%,
respectively. Median progression-free survival (PFS) was between
5 and 10.5 months (Table 3).
3.5. Subsequent stem cell transplant facilitated by brentuximab
vedotin
SCT after brentuximab vedotin treatment was reported by trans-
plant type in two  cohorts (Table 2). Among 241 patients treated
in French centers, 12% received subsequent ASCT and 11% under-
went alloSCT (Perrot et al., 2014). A study of 58 patients in Turkey
reported subsequent ASCT and alloSCT in 3% and 21% of patients,
respectively. All ﬁve patients who received SCT in CR (1 ASCT; 4
alloSCT) were in continuous CR 1–12 months after transplantation,
while 0/9 patients who received SCT while in stable or progres-
sive disease obtained a remission post-SCT (Ferhanoglu et al., 2014;
Salihoglu et al., 2015).In a series of 10 patients in Turkey who  had relapsed after ASCT,
six went on to receive alloSCT after treatment with brentuximab
vedotin (Erdem et al., 2014). In an Italian study, 7/20 patients (35%)
who were ASCT-ineligible, and 15/25 patients (60%) who  had failed
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Table  3
Reported efﬁcacy of brentuximab vedotin in patients with R/R HL treated under the NPP.
NPP cohort Best response Survival
n evaluable/N ORR [CR + PR],
%
CR, % Median cycle
number to best
response
(range)
Median DOR,
months
Median follow-up,
months (range)
Median OS, months Median PFS,
months
Erdem et al.
(2014)
After 6 cycles:
10/10
After 6 cycles:
80
After 6 cycles:
10
NR NR NR NR NR
Perrot et al.,
2014
223/241 58a (32a at end
of treatment)
32a
(23a at end of
treatment)
4 (NR) 8 16 (NR) Not reached
(1-yr: 76%,
2-yr: 58%)
7
Viviani et al.
(2015)b
A: 20/20
B: 25/25
A: 75
B: 64
A: 40
B: 20
3 (2–9) NR 14 (1–36) Not reached
(2-yr: 60%c)
5
Salihoglu et al.
(2015)
Ferhanoglu
et al. (2014)
Between 2–5
cycles: 49/58
After ≥6 cycles:
37/58
Between 2–5
cycles: 63
After ≥6 cycles:
32
Between 2–5
cycles: 27
After ≥6 cycles:
22
NR 9 NR Not reached
(1-yr: 71%)
7
(1-yr: 33%)
Tsirigotis et al.
(2015)
77/80 58 18 NR NR 9.5 (1–35) 31 10.5
Carlo-Stella
et al. (2015)
Ricci et al.
(2014)
16/16 69 31 4 (2–12) 5 26 (5–30) 25
(2-yr: 61%)
7
(2-yr: 20%)
Yang et al.
(2014)
21/22d 73d 18d NR
Time to
response in
months: 0.9
(0.7–3.0)
4.4 (1.0–17.4) NR Not reached
(1-yr: 67%)
5.7
Zallio et al.
(2014)
8/8 NR 25 NR NR 12 NR NR
AlloSCT, allogeneic stem cell transplant; ASCT, autologous stem cell transplant; CR, complete remission; CRu, unconﬁrmed; DOR, duration of response; HL, Hodgkin lymphoma;
ITT,  intention to treat; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial remission; NPP, named patient program; NR, not reported;
R/R,  relapsed/refractory; yr, year.
a Includes CRu.
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2b Data for some parameters only available by group (A, patients ineligible for ASC
c 2-year OS was 70% in Group A and 53% in Group B.
d Although one patient was  not evaluable for response, response rates are report
rior ASCT went on to receive a transplant procedure following
reatment with brentuximab vedotin (Viviani et al., 2015). Among
 separate cohort of 12 patients from Italy who were undergoing
educed-intensity conditioning (RIC) alloSCT following a relapse
fter ASCT, eight had received brentuximab vedotin as a bridge
o the allografting procedure. Seven of the eight patients (88%)
ngrafted; one patient relapsed at 8 months, and the others were
live and progression-free at 12 months (Zallio et al., 2014). In
6 patients from Italy who had failed both ASCT and alloSCT, one
atient discontinued brentuximab vedotin due to availability of a
onor for a second alloSCT (no further information is provided;
Carlo-Stella et al., 2015; Ricci et al., 2014)).
.6. Safety of brentuximab vedotin
Available adverse event (AE) data are summarized in Table 4. In
he two largest cohorts (n = 299), any-grade neuropathy occurred
n 28–31% of patients, and grade 3/4 neuropathy was  reported
n 2–3% of patients (Ferhanoglu et al., 2014; Perrot et al., 2014;
alihoglu et al., 2015). Any-grade hematologic toxicities reported in
hese cohorts included anemia, thrombocytopenia, and neutrope-
ia; grade 3/4 neutropenia occurred in 2–7% of patients. Among
he three smaller cohorts, reports of grade ≥3 hematologic AEs
ncluded neutropenia (13–32%), anemia (15%), and thrombocy-
openia (12–14%) (Carlo-Stella et al., 2015; Ricci et al., 2014; Viviani
t al., 2015; Yang et al., 2014). Other any-grade AEs for which
ncidence was reported in >1 cohort included nausea, pneumonia,
yalgia/muscle pain, constipation, and pyrexia/fever.
Dose reductions were described for 9/80 patients (11%) in two
ohorts (Ferhanoglu et al., 2014; Salihoglu et al., 2015; Yang et al.,
014), and 17% of patients in the French cohort (N = 241) required 20]; B, patients who had failed prior ASCT [n = 25]).
n intention-to-treat analysis, i.e., n = 22.
≥1 dose adaptation (Perrot et al., 2014). Comprehensive discontin-
uation data were only available for the large French cohort, where
222 patients (92%) discontinued brentuximab vedotin, mainly
because of progression (54%), but also to receive a transplant (25%)
and due to AEs (5%) (Perrot et al., 2014). One Italian study (N = 45)
reported that no patients discontinued treatment due to toxicity
(Viviani et al., 2015), while in another, it was noted that 2/5 patients
achieving CR discontinued due to toxicity (Carlo-Stella et al., 2015;
Ricci et al., 2014).
Two studies reported that there were no deaths related to bren-
tuximab vedotin (Carlo-Stella et al., 2015; Perrot et al., 2014; Ricci
et al., 2014). One study reported the death of a patient who received
a donor-lymphocyte infusion during treatment with brentuximab
vedotin; the patient died after the development of stage IV pul-
monary graft-versus-host-disease (GVHD) (Carlo-Stella et al., 2015;
Ricci et al., 2014). Another study reported the death of a patient due
to pneumonia after one cycle of brentuximab vedotin (Yang et al.,
2014).
4. Discussion
In our previous review, pooled analysis of NPP data in R/R
HL demonstrated similar efﬁcacy and tolerability of brentuximab
vedotin in the real-world setting to the pivotal phase 2 trial results
(Zinzani et al., 2015; Younes et al., 2012). The pooled ORR and CR
rate for all R/R HL cohorts was 67% and 26%, respectively, which
compared with phase 2 rates of 75% and 34% (Zinzani et al., 2015;
Younes et al., 2012). Among three NPP R/R HL cohorts, median PFS
ranged from 6.8 to 9.0 months (Rothe et al., 2012; Sasse et al., 2013;
Zinzani et al., 2013), which compared with a phase 2 report of 5.6
months (Younes et al., 2012). Median OS had not been reached in
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Table  4
Reported tolerability of brentuximab vedotin in patients with R/R HL treated under the NPP.
NPP cohorta N Neurologic adverse events Hematologic adverse events Other adverse events
Any grade, % Grade 3/4, % Any grade, % Grade 3/4, % Any grade, % Grade 3/4, %
Perrot et al.,
2014
241 Peripheral
sensory
neuropathy:
28b
Peripheral
sensory
neuropathy: 2b
Anemia: 39b
Thrombocy-
topenia: 27b
Neutropenia:
23b
Neutropenia:
7b
Diarrhea: 14b
Viviani et al.
(2015)
45 Peripheral
sensory
neuropathy: 4c
Neutropenia:
13c
Pneumonia: 2c
Salihoglu et al.
(2015)
Ferhanoglu
et al. (2014)
58 Neuropathy: 31
Oculomotor
nerve palsy: 2
Generalized
tonic
convulsions: 3
Neuropathy: 3 Neutropenia:
28
Neutropenia: 2 Fatigue: 50
Nausea: 33
Vomiting; 26
Myalgia: 26
Alopecia: 21
Extremity pain:
21
Pyrexia: 14
Muscle spasm:
14
Constipation:
12
Pruritus: 12
Nausea: 3
Myalgia: 3
Extremity pain:
3
Vomiting: 2
Carlo-Stella
et al. (2015)
Ricci et al.
(2014)
16 Peripheral
sensory
neuropathy:
31c
Peripheral
sensory
neuropathy: 6d
Guillain-Barré
syndrome: 6
Neutropenia:
18c
Anemia: 15c
Thrombocytopenia:
12c
Infections: 19
Fever
(unknown
origin): 13
Yang et al.
(2014)
22 Sensory
neuropathy: 0b
Neutropenia:
32b
Thrombocytopenia;
14b
Pneumonia: 5b
Hemorrhagic
cystitis: 5b
Nausea: 5b
Constipation:
5b
Muscle pain: 5b
HL, Hodgkin lymphoma; NPP, named patient program; R/R, relapsed/refractory.
a Speciﬁc details of adverse events were not available for 3 of the 8 patient cohorts.
b Treatment-related adverse events.
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d Discrepancy in published report (abstract states two  patients with grade 3 perip
ensory neuropathy; if n = 2 then percentages with any grade and grade 3/4 periphe
he four HL cohorts that reported OS data (Rothe et al., 2012; Sasse
t al., 2013; Zinzani et al., 2013; Garciaz et al., 2014). With regard
o safety, the overall rate and intensity of toxicities reported in the
PP were similar to those seen in the registrational phase 2 trial
Younes et al., 2012), albeit with slightly lower rates of individual
Es, possibly due to under-reporting of AEs in the NPP or differences
n the number of cycles administered (Zinzani et al., 2015).
The results of this updated NPP analysis (480 patients with R/R
L) support the previous NPP ﬁndings in R/R HL (207 patients
ith a speciﬁed diagnosis of R/R HL). Although it was  not possible
o determine the extent of overlap between the patient popula-
ions included in the two analyses, the current review includes
t least 126 new patients versus our original review, in four new
ohorts which were not previously described, as well as new partic-
pating countries. This represents a substantial increase in patient
umbers, and these data add to the growing body of evidence
emonstrating the efﬁcacy and safety of brentuximab vedotin in
eal-world clinical practice. The observed response rates (ORR
8–80%; CR rate 10–40%) and median times to events (PFS 5–10.5
onths; OS 25–31 months) are consistent with those reported in
ur original review and in the pivotal phase 2 trial (Zinzani et al.,
015; Younes et al., 2012). Interestingly, response rates and OS data
or patients in the new cohorts from Asia and Turkey were compara-
le to those seen in Western patients treated within the NPP (Erdem
t al., 2014; Ferhanoglu et al., 2014; Salihoglu et al., 2015; Yang
t al., 2014). As reported previously (Zinzani et al., 2015), responses
o brentuximab vedotin were rapid, typically occurring within the sensory neuropathy and results section states one patient with grade 3 peripheral
nsory neuropathy would be 38% and 13%, respectively).
ﬁrst 3–4 cycles. The speed of response illustrates the importance of
assessing response soon after treatment is initiated and highlights
a need to clarify optimal timing of ﬁrst staging to ensure consis-
tent evaluation in the real-world setting. Brentuximab vedotin’s
tolerability proﬁle was  as expected from the previous NPP report
and clinical trial data (Zinzani et al., 2015; Younes et al., 2012;
Moskowitz et al., 2015), with generally manageable toxicities.
As discussed in our original review, this type of analysis is
associated with a number of intrinsic limitations, such as report-
ing/selection bias and heterogeneous reporting. While the strength
of any conclusions that can be drawn is therefore limited, the data
reviewed here are similar to those reported previously (Zinzani
et al., 2015; Younes et al., 2012). In summary, this updated review
of published NPP data supports the ﬁndings of our original litera-
ture review, which showed comparable efﬁcacy and tolerability of
brentuximab vedotin in real-world practice to phase 2 trial results
in R/R HL.
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